BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23835331)

  • 1. Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor.
    Gallagher EJ; Alikhani N; Tobin-Hess A; Blank J; Buffin NJ; Zelenko Z; Tennagels N; Werner U; LeRoith D
    Diabetes; 2013 Oct; 62(10):3553-60. PubMed ID: 23835331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating new therapeutic strategies targeting hyperinsulinemia's mitogenic effects in a female mouse breast cancer model.
    Rostoker R; Bitton-Worms K; Caspi A; Shen-Orr Z; LeRoith D
    Endocrinology; 2013 May; 154(5):1701-10. PubMed ID: 23515289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes.
    Ferguson RD; Novosyadlyy R; Fierz Y; Alikhani N; Sun H; Yakar S; Leroith D
    Breast Cancer Res; 2012 Jan; 14(1):R8. PubMed ID: 22226054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.
    Novosyadlyy R; Lann DE; Vijayakumar A; Rowzee A; Lazzarino DA; Fierz Y; Carboni JM; Gottardis MM; Pennisi PA; Molinolo AA; Kurshan N; Mejia W; Santopietro S; Yakar S; Wood TL; LeRoith D
    Cancer Res; 2010 Jan; 70(2):741-51. PubMed ID: 20068149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor.
    Milazzo G; Sciacca L; Papa V; Goldfine ID; Vigneri R
    Mol Carcinog; 1997 Jan; 18(1):19-25. PubMed ID: 9022809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
    Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
    Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome and colorectal cancer: is hyperinsulinemia/insulin receptor-mediated angiogenesis a critical process?
    Liu JJ; Druta M; Shibata D; Coppola D; Boler I; Elahi A; Reich RR; Siegel E; Extermann M
    J Geriatr Oncol; 2014 Jan; 5(1):40-8. PubMed ID: 24484717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines.
    Shukla A; Grisouard J; Ehemann V; Hermani A; Enzmann H; Mayer D
    Endocr Relat Cancer; 2009 Jun; 16(2):429-41. PubMed ID: 19153208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
    Gallagher EJ; Fierz Y; Vijayakumar A; Haddad N; Yakar S; LeRoith D
    Oncogene; 2012 Jul; 31(27):3213-22. PubMed ID: 22037215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling.
    Pandini G; Vigneri R; Costantino A; Frasca F; Ippolito A; Fujita-Yamaguchi Y; Siddle K; Goldfine ID; Belfiore A
    Clin Cancer Res; 1999 Jul; 5(7):1935-44. PubMed ID: 10430101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells.
    Balañá ME; Labriola L; Salatino M; Movsichoff F; Peters G; Charreau EH; Elizalde PV
    Oncogene; 2001 Jan; 20(1):34-47. PubMed ID: 11244498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducible expression of dominant negative insulin-like growth factor I receptor in MCF-7 breast cancer cells.
    Modha G; Blanchard A; Sidorchuk J; Venditti M; Shiu R; Myal Y
    Endocrine; 2003 Dec; 22(3):293-303. PubMed ID: 14709803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I.
    Liefvendahl E; Arnqvist HJ
    Horm Metab Res; 2008 Jun; 40(6):369-74. PubMed ID: 18393172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential phosphorylation of IRS-1 and IRS-2 by insulin and IGF-I receptors.
    Rakatzi I; Stosik M; Gromke T; Siddle K; Eckel J
    Arch Physiol Biochem; 2006 Feb; 112(1):37-47. PubMed ID: 16754202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function.
    Feng Y; Zhu Z; Xiao X; Choudhry V; Barrett JC; Dimitrov DS
    Mol Cancer Ther; 2006 Jan; 5(1):114-20. PubMed ID: 16432169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.
    Law JH; Habibi G; Hu K; Masoudi H; Wang MY; Stratford AL; Park E; Gee JM; Finlay P; Jones HE; Nicholson RI; Carboni J; Gottardis M; Pollak M; Dunn SE
    Cancer Res; 2008 Dec; 68(24):10238-46. PubMed ID: 19074892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors.
    Campbell CI; Moorehead RA
    BMC Cancer; 2011 Nov; 11():480. PubMed ID: 22070644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.